News

The grant was given to Leonard Zon, MD, of Boston Children’s Hospital who will collaborate extensively with other scientists at Boston Children’s Hospital and Dana-Farber Cancer Institute, including Scott A. Armstrong, MD, PhD; Vijay G. Sankaran, MD, PhD; Fernando Camargo, PhD; and Serine Avagyan, MD, PhD.

A report by Dana-Farber/Boston Children's researchers on the study of video conferencing was published in the journal Pediatric Blood and Cancer.

His remarkable body of work has not only revolutionized our understanding of how these illnesses occur but has also led to promising new gene-based therapies for thalassemia and sickle cell disease, two inherited blood disorders that affect millions of people around the world.

Genomic testing of patient leukemia cells uncovers genetic alterations that can be targeted by drug therapies in many patients.

Established in 2015 and supported by the Tobias Foundation, the prize recognizes original and promising basic hematology research as well as direct translational or clinical research related to cell therapy in hematological disorders.

Abatacept (Orencia) reduces rates of acute GVHD, boosts survival in Phase 2 multicenter trial.

Boston magazine has named a number of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center faculty members to its annual "Top Doctors" guide.

The gift will support pediatric research, holiday gifts, and virtual events for pediatric patients and their families as part of the company’s global Amazon Goes Gold campaign during Childhood Cancer Awareness Month.

U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the top pediatric cancer program in New England and #2 in the nation in its 2020-21 Best Children's Hospitals report.

A collaboration between the Finnish Cancer Registry and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center explored the utility of population-based registry data to screen childhood cancer patients for history of familial cancer. The study opened a new method for identifying high risk families that may reveal possible novel cancer predisposition genes.